Accueil   Diary - News   All news Vetbiobank obtained an authorization for manufacturing veterinary cell-based therapy

Vetbiobank obtained an authorization for manufacturing veterinary cell-based therapy

Vetbiobank confirms its leading position in veterinary regenerative medicine by obtaining for its new facility the first authorization issued in France for manufacturing veterinary cell-based therapy.

 

Since 2011 Vetbiobank has brought to light the potential of neonatal mesenchymal stem cells to successfully treat animal chronic inflammatory diseases.


In just a few years, we have been able to demonstrate to:
- The scientific and veterinary community, the remarkable long-term efficacy of our neonatal stem cells for chronic inflammatory conditions (Cabon et al, Frontiers Vet Science 2019; Taroni et al, Frontiers Vet Sci. 2017).
- Horse and dog’s owners that our products are produced through an ethical process using stem cells collected at birth, therefore respecting completely animal welfare (i.e. without medical or surgical intervention impacted on the donor).
- Industrial partners, the business potential of our product, with an initial contract renewed in May 2019 for the development of canine osteoarthritis treatment.
- Investors the management’s ability to deliver value, and in return they showed their faith during the company’s 2019 financial round, by contributing more than one million euros.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree